The best indicator for Boston Scientific (BSX)
We backtested 366 indicators across daily, weekly and hourly charts on real Boston Scientific (BSX) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
CCI (100)
On the weekly chart, this is the strongest risk-adjusted edge we found for Boston Scientific (BSX) over ~34.2 years — beating buy-and-hold by 4.5% CAGR.
Best multi-indicator combo
Going long only when all 2 agree was the strongest confluence setup we found for Boston Scientific (BSX) — trailing buy-and-hold by 0.5% CAGR, out-of-sample. Fewer, higher-conviction trades than any single indicator.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | CCI (100) ✓ | Weekly | 11.6% | 0.58 | -53.3% | 38.9% | 18 | 4.5% |
| 2 | DEMA 200 Trend ✓ | Weekly | 8.5% | 0.57 | -37.7% | 45.8% | 24 | 1.3% |
| 3 | TRIMA 100 Trend ✓ | Weekly | 11.6% | 0.59 | -61.3% | 50.0% | 14 | 4.4% |
| 4 | EMA 100 Trend ✓ | Weekly | 10.8% | 0.54 | -55.4% | 30.8% | 26 | 3.6% |
| 5 | Disparity (100) ✓ | Weekly | 10.8% | 0.54 | -55.4% | 30.8% | 26 | 3.6% |
| 6 | Bollinger Squeeze ✓ | Weekly | 8.1% | 0.53 | -40.2% | 51.9% | 27 | 0.9% |
| 7 | G-Channel ✓ | Weekly | 10.5% | 0.53 | -50.6% | 41.9% | 31 | 3.3% |
| 8 | T3 15/60 Cross ✓ | Daily | 10.1% | 0.52 | -68.8% | 48.4% | 64 | 2.7% |
| 9 | MA Ribbon ✓ | Weekly | 8.6% | 0.52 | -65.0% | 40.7% | 27 | 1.4% |
| 10 | SMA 100 Trend ✓ | Weekly | 10.0% | 0.52 | -55.4% | 44.4% | 27 | 2.8% |
| 11 | WMA 100 Trend ✓ | Weekly | 9.8% | 0.52 | -62.4% | 40.0% | 30 | 2.6% |
| 12 | RSI (50) ✓ | Weekly | 10.3% | 0.52 | -55.4% | 31.0% | 29 | 3.1% |
| 13 | Keltner 50 (x2.0) ✓ | Weekly | 7.3% | 0.52 | -46.6% | 45.5% | 55 | 0.1% |
| 14 | Linear Regression Slope ✓ | Weekly | 10.0% | 0.5 | -59.1% | 48.7% | 39 | 2.9% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Boston Scientific (BSX), CCI (100) on the weekly timeframe gave the best balance of return and risk in our test. It beat buy-and-hold — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.